7:30 am Check-In & Coffee
8:35 am Chair’s Opening Remarks
8:45 am Industry Leader’s Fireside Chat: Discussing the Scope & Landscape of Cell Therapy for Neurological Disease
Synopsis
- How can we use the successes and lessons learned from cell therapies in oncology to inform and improve treatments for neurological diseases?
- Outlining the progress in this space and spotlighting achievements from leading companies in the field
- Reaffirming the importance and relevance for cell therapies for neurological disorders in comparison to other treatment modalities
9:30 am Data Showcase: Unveiling New Data Highlighting the Promise of Cell Therapies for Neurological Disorders
Synopsis
- Presenting recent data demonstrating promising preclinical/clinical results to highlight the progression in this field
- Analyzing the data to consider the implications and future directions to map out the next steps
- Contextualizing data by considering methods as well as examining data limitations
10:00 am Morning Break & Speed Networking
Synopsis
As this community unites, this session will provide valuable networking time with your peers, enabling you to forge new and lasting connections.
Focusing on Cell Sources Aiming to Overcome Challenges to Unleash the Potential of these Therapies
11:00 am Navigating Cell Type Composition & Purification Techniques to Ensure Patient Safety & Improve Efficacy
Synopsis
- Cultivating a deeper understanding of cell type composition and transition trajectory to ensure improved purity
- Clarifying the criteria set by regulators on purity to avoid regulatory hurdles
- Thinking about cell differentiation after transplantation to predict effects of this
11:30 am Addressing Somatic Mutations for Cell Therapies to Consider How This Could Affect Treatment
Synopsis
- Exploring how genetic variations in donor cells can influence the efficacy and safety of iPSC-based therapies
- Evaluating the potential differences in somatic mutation profiles between skin and bloodderived iPSCs, and their implications for treatment outcomes
- Discussing strategies to identify and mitigate potential safety concerns associated with somatic mutations in iPSC-derived cell therapies
12:00 pm Scaling the Future: Manufacturing & Clinical Strategies in Cell Therapy for Neurological Disorders
Synopsis
- Using clinical data from neurological studies to build strong manufacturing processes and secure strategic partnerships in the cell therapy space
- Addressing the unique challenges of bringing cell therapies for neurological conditions from concept to clinic, including indication selection and manufacturing scale-up
- Ensuring success in cell therapy for neurological disorders by focusing on material control, reproducibility, and scalability
12:30 pm Lunch Break & Networking
12:30 pm Developing iPSC-Derived Products for Alzheimer’s & Parkinson’s Disease
Synopsis
- Integrating novel differentiation protocols to produce high-quality iPSC-derived cell types Optimizing manufacturing processes for scalable and consistent production of therapeutic products
- Addressing regulatory requirements to expedite the development and approval of iPSCbased therapies
Analyzing Delivery, Administration & Accessibility to Review which Patients these Treatments are Possible for, Whilst Addressing the Ethical Concerns
2:30 pm Expert Discussion: Are Placebo’s Necessary & Ethical when Treatment Includes Invasive Surgeries?
Synopsis
- Centering the patient experience before surgery to empathize with the difficulties in deciding to go forward with these treatments
- Exploring how effective double-blind trials are in these circumstances, considering that patients will be aware if they did not undergo surgery
- Discussing ethical concerns regarding placebo testing in the context of regulation
3:00 pm Afternoon Break & Poster Session
Synopsis
This is your opportunity to contribute to the conversation and share your cutting-edge research with this community while discovering exciting work carried out by your peers. To submit a poster, please contact info@hansonwade.com.
Benchmarking Best Practice to Set the Right Endpoint & Evaluate Differing Opinions on Immunosuppression
3:30 pm Roundtable Discussion: Exploring Scoring Systems that are Used to Set Endpoints to Consider which System is Best to Assess Efficacy
Synopsis
- How can scoring systems accurately represent progress due to treatment in disorders with a very wide range of symptoms? (i.e. motor, language, cognitive etc)
- Exploring a range of different scoring system types to select the system most suitable for your pipeline
4:00 pm Patient Perspectives: Evaluating Differing Views on Immunosuppression by Breaking Down Existing Literature & Patient Experience
Synopsis
- How long (if at all) do you need to immune-suppress?
- What would be the clinical immune-suppression measurement that would be justifiable based on existing data?
- Reviewing the advantages and disadvantages of immunosuppression for the patient